Difference between revisions of "Dasatinib (Sprycel)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Oral chemotherapy" to "Category:Oral medications") |
|||
| Line 18: | Line 18: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
*6/28/2006: FDA approved for the treatment of adults with [[Chronic myelogenous leukemia | chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia]] with resistance or intolerance to prior therapy including [[Imatinib (Gleevec) | imatinib]]. Also indicated for the treatment of adults with [[Acute lymphocytic leukemia | Philadelphia chromosome-positive acute lymphoblastic leukemia]] with resistance or intolerance to prior therapy. | *6/28/2006: FDA approved for the treatment of adults with [[Chronic myelogenous leukemia | chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia]] with resistance or intolerance to prior therapy including [[Imatinib (Gleevec) | imatinib]]. Also indicated for the treatment of adults with [[Acute lymphocytic leukemia | Philadelphia chromosome-positive acute lymphoblastic leukemia]] with resistance or intolerance to prior therapy. | ||
| − | *10/28/2010: New indication for | + | *10/28/2010: New indication for newly diagnosed adults with [[Chronic myelogenous leukemia | Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase]]. |
| + | *11/10/2017: New FDA indication for the treatment of pediatric patients with [[Chronic myelogenous leukemia |Philadelphia chromosome-positive chronic myeloid leukemia]] in chronic phase. | ||
==Also known as== | ==Also known as== | ||
Revision as of 17:38, 10 November 2017
General information
Class/mechanism: Tyrosine kinase inhibitor of BCR-ABL, the SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ. Binds to multiple conformations of the ABL kinase.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Dasatinib (Sprycel) package insert[1]
- Dasatinib (Sprycel) patient drug information (Chemocare)[4]
- Dasatinib (Sprycel) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 6/28/2006: FDA approved for the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia with resistance or intolerance to prior therapy including imatinib. Also indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy.
- 10/28/2010: New indication for newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.
- 11/10/2017: New FDA indication for the treatment of pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.
Also known as
BMS-354825
References
Categories:
- Drug index
- Chemotherapy
- Oral medications
- Kinase inhibitors
- Bcr-Abl inhibitors
- BTK inhibitors
- KIT inhibitors
- PDGFR inhibitors
- SRC inhibitors
- SYK inhibitors
- Acute lymphocytic leukemia medications
- Chronic myelogenous leukemia medications
- Systemic mastocytosis medications
- Drugs FDA approved in 2006
- WHO Essential Cancer Medicine